CD274 and hepatocellular carcinoma: Lastly, durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) are used for non-small cell lung cancer and hepatocellular carcinoma, enhancing the immune response by targeting different checkpoints [42–44].